Stock Market Reviews

LVTX (LAVA Therapeutics N.V.) News

Get the latest news, insights, and market updates on LVTX (LAVA Therapeutics N.V.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Xoma strikes deals to buy struggling biotechs HilleVax, Lava
  The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the sector’s struggles continue.
  Aug 4, 2025 - $LVTX
• Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation
  Just because a business does not make any money, does not mean that the stock will go down. For example, although...
  May 16, 2025 - $LVTX
• LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
  Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to progressCash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on its proprietary Gammab
  May 14, 2025 - $LVTX
• LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
  Exemption from the $5.1 million repayment obligation strengthens LAVA’s balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksd
  Apr 16, 2025 - $LVTX
• LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
  Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266Phase 1 enrollment in LAVA-1266 clinical trial underwayJohnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027 UTRECHT, The Netherlands and P
  Mar 28, 2025 - $LVTX
• LAVA Announces Evaluation of Strategic Options
  Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that the Company has initiated a process to review strategic options focused
  Feb 25, 2025 - $LVTX
• LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
  LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1 data read-out expected by year-end 2025 UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing
  Jan 10, 2025 - $LVTX
• LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
  Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA-1207Fourth quarter pipeline advances include initiation of the Phase 1 trial for LAVA-1266, for hematologic malignancies, and a $5.0 million milestone payment from Johnson and JohnsonCash runway extended into 2027, based on a cash balance of $78.9 million, as of September 30, 2024 UTRECHT, The Neth
  Dec 10, 2024 - $LVTX